Journal: Gut and Liver

Article Title: High Expression of Aldo-Keto Reductase 1B10 Is an Independent Predictor of Favorable Prognosis in Patients with Hepatocellular Carcinoma

doi: 10.5009/gnl13406

Figure Lengend Snippet: Immunostaining of Aldo-Keto Reductase 1B10 showing cytoplasmic immunoreactivity in hepatocellular carcinoma tissue (horse-radish peroxidase stain, ×200).

Article Snippet: The sections were incubated with a primary antibody against AKR1B10 (mouse monoclonal antibody, clone 1A6, 1:800; Abnova Corp., Taipei, Taiwan) for 30 minutes at room temperature.

Techniques: Immunostaining, Staining

Journal: Gut and Liver

Article Title: High Expression of Aldo-Keto Reductase 1B10 Is an Independent Predictor of Favorable Prognosis in Patients with Hepatocellular Carcinoma

doi: 10.5009/gnl13406

Figure Lengend Snippet: Correlation between Aldo-Keto Reductase 1B10 Expression and the Clinicopathologic Features of 255 Hepatocellular Carcinomas

Article Snippet: The sections were incubated with a primary antibody against AKR1B10 (mouse monoclonal antibody, clone 1A6, 1:800; Abnova Corp., Taipei, Taiwan) for 30 minutes at room temperature.

Techniques: Expressing

Journal: Gut and Liver

Article Title: High Expression of Aldo-Keto Reductase 1B10 Is an Independent Predictor of Favorable Prognosis in Patients with Hepatocellular Carcinoma

doi: 10.5009/gnl13406

Figure Lengend Snippet: Univariate and Multivariate Logistic Regression Models for the Prediction of Early Tumor Recurrence in 255 Patients with Hepatocellular Carcinoma

Article Snippet: The sections were incubated with a primary antibody against AKR1B10 (mouse monoclonal antibody, clone 1A6, 1:800; Abnova Corp., Taipei, Taiwan) for 30 minutes at room temperature.

Techniques: Expressing

Journal: Gut and Liver

Article Title: High Expression of Aldo-Keto Reductase 1B10 Is an Independent Predictor of Favorable Prognosis in Patients with Hepatocellular Carcinoma

doi: 10.5009/gnl13406

Figure Lengend Snippet: Univariate Analyses of the Recurrence-Free Survival and the Disease-Specific Survival in 255 Patients with Hepatocellular Carcinoma

Article Snippet: The sections were incubated with a primary antibody against AKR1B10 (mouse monoclonal antibody, clone 1A6, 1:800; Abnova Corp., Taipei, Taiwan) for 30 minutes at room temperature.

Techniques: Expressing

Journal: Gut and Liver

Article Title: High Expression of Aldo-Keto Reductase 1B10 Is an Independent Predictor of Favorable Prognosis in Patients with Hepatocellular Carcinoma

doi: 10.5009/gnl13406

Figure Lengend Snippet: Kaplan-Meier survival curves showing recurrence-free survival (A) and disease-specific survival (B) according to Aldo-Keto Reductase 1B10 expression in 255 hepatocellular carcinomas.

Article Snippet: The sections were incubated with a primary antibody against AKR1B10 (mouse monoclonal antibody, clone 1A6, 1:800; Abnova Corp., Taipei, Taiwan) for 30 minutes at room temperature.

Techniques: Expressing

Journal: Gut and Liver

Article Title: High Expression of Aldo-Keto Reductase 1B10 Is an Independent Predictor of Favorable Prognosis in Patients with Hepatocellular Carcinoma

doi: 10.5009/gnl13406

Figure Lengend Snippet: Multivariate Analyses of the Recurrence-Free Survival and the Disease-Specific Survival in 255 Patients with Hepatocellular Carcinoma

Article Snippet: The sections were incubated with a primary antibody against AKR1B10 (mouse monoclonal antibody, clone 1A6, 1:800; Abnova Corp., Taipei, Taiwan) for 30 minutes at room temperature.

Techniques: Expressing

Journal: Frontiers in Immunology

Article Title: Ribosome biogenesis-related gene signature predicts prognosis and immune landscape in glioma and identifies UTP20 as a therapeutic target

doi: 10.3389/fimmu.2025.1680667

Figure Lengend Snippet: Construction of a Ribosome biogenesis-related gene signature based on the TCGA glioma cohort. (A) Volcano map displayed the genes that affected the survival of glioma patients. (B) Venn diagram showing the intersection of 331 RBRGs with risky genes from TCGA. (C) LASSO regression analysis narrowing down to 22 candidate genes. (D) Univariate and (E) multivariate Cox regression selecting 4 independent prognostic genes. (F) Genomic map showing specific localization of NOP10, UTP20, SHQ1, and PIH1D2 in chromosomes. (G) Circos plot showing the correlation among these 4 genes. (H) Kaplan–Meier survival analysis of glioma patients in the RBRGs-high and -low groups using the TCGA cohort. (I) Scatter plot demonstrating survival time and number of deaths in the two groups. (J) Time-dependent ROC curves demonstrating the predictive accuracy of RBRGs for 1-, 3-, and 5-year survival in glioma patients.

Article Snippet: The membranes were blocked with 5% skimmed milk and then incubated overnight at 4 °C with primary antibodies: UTP20 (Proteintech, 18830-1-AP) and β-actin (Abmart, P30002 ).

Techniques:

Journal: Frontiers in Immunology

Article Title: Ribosome biogenesis-related gene signature predicts prognosis and immune landscape in glioma and identifies UTP20 as a therapeutic target

doi: 10.3389/fimmu.2025.1680667

Figure Lengend Snippet: Validation of RBRGs expression levels and prognostic value was based on multiple cohorts. (A, B) TCGA and GSE16011 cohorts were used to validate the expression levels of NOP10, UTP20, SHQ1, PIH1D2, and RBRGs in normal and glioma tissues, respectively. (C–E) The Kaplan-Meier curves, scatter plots, and time-dependent ROC curves were utilized to validate the prognostic value of RBRGs in glioma using the CGGA301, CGGA325, and GSE43378 cohorts. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Article Snippet: The membranes were blocked with 5% skimmed milk and then incubated overnight at 4 °C with primary antibodies: UTP20 (Proteintech, 18830-1-AP) and β-actin (Abmart, P30002 ).

Techniques: Biomarker Discovery, Expressing

Journal: Frontiers in Immunology

Article Title: Ribosome biogenesis-related gene signature predicts prognosis and immune landscape in glioma and identifies UTP20 as a therapeutic target

doi: 10.3389/fimmu.2025.1680667

Figure Lengend Snippet: Role of RBRGs in the tumor microenvironment. (A) Differences in infiltration of immune cells between RBRGs-high and -low groups based on the CIBERSORTx algorithm. (B) Heatmap showing the correlation of NOP10, UTP20, SHQ1, and PIH1D2 with immune cells. (C–E) Differences in MDSC, CAF, and ESTIMATE scores between RBRGs-high and -low groups. (F) Heatmap showing the correlation of NOP10, UTP20, SHQ1, and PIH1D2 with ESTIMATE score. (G) Differences in immune subtypes between RBRGs-high and -low groups. (H) Kaplan-Meier curve showing the effect of immune subtype on overall survival of glioma patients. C1: wound healing, C3: inflammatory, C4: lymphocyte depleted, C5: immunologically quiet. (I, J) Single-cell analysis demonstrating the expression levels of NOP10, UTP20, SHQ1, and PIH1D2 in different cells based on the GSE131928 cohort. *p < 0.05, **p < 0.01, ***p < 0.001.

Article Snippet: The membranes were blocked with 5% skimmed milk and then incubated overnight at 4 °C with primary antibodies: UTP20 (Proteintech, 18830-1-AP) and β-actin (Abmart, P30002 ).

Techniques: Single-cell Analysis, Expressing

Journal: Frontiers in Immunology

Article Title: Ribosome biogenesis-related gene signature predicts prognosis and immune landscape in glioma and identifies UTP20 as a therapeutic target

doi: 10.3389/fimmu.2025.1680667

Figure Lengend Snippet: RBRGs predicted the efficacy of immunotherapy. Differences in cancer-immunity cycle between patients in the RBRGs-high and -low groups were based on the TCGA glioma cohort. (A) Step 1: release of cancer cell antigens. (B) Step 2: cancer antigen presentation. (C) Step 3: priming and activation. (D) Step 4: trafficking of immune cells to tumors. (E) Step 5: infiltration of immune cells into tumors. (F) Step 6: recognition of cancer cells by T cells. (G) Step7: killing of cancer cells. (H) Differential expression of immunosuppressive checkpoints in RBRGs-high and -low groups. (I) Heatmap demonstrating the correlation of NOP10, UTP20, SHQ1, and PIH1D2 with multiple immunosuppressive checkpoints. (J-M) Kaplan-Meier curves demonstrating RBRGs combined with CD274, PDCD1, PDCD1LG2, or TNFRSF18 respectively, to predict overall survival in glioma patients. (N) Differences in TIDE scores between RBRGs-high and -low groups. (O, P) Differences in survival between patients in the RBRGs-high and -low groups receiving immunotherapy were analyzed based on the glioma PRJNA482620 and melanoma GSE91061 cohorts. *p < 0.05, **p < 0.01, ***p < 0.001, **** p < 0.0001.

Article Snippet: The membranes were blocked with 5% skimmed milk and then incubated overnight at 4 °C with primary antibodies: UTP20 (Proteintech, 18830-1-AP) and β-actin (Abmart, P30002 ).

Techniques: Immunopeptidomics, Activation Assay, Quantitative Proteomics

Journal: Frontiers in Immunology

Article Title: Ribosome biogenesis-related gene signature predicts prognosis and immune landscape in glioma and identifies UTP20 as a therapeutic target

doi: 10.3389/fimmu.2025.1680667

Figure Lengend Snippet: Genetic mutations. (A) The oncoplot depicted genetic mutations differences in glioma patients between RBRGs-high and -low groups. (B) Kaplan-Meier curves demonstratingthe difference in overall survival of glioma patients between the EGFR, NF1 and PTEN mutation and wild-type groups. (C) Differential expression of NOP10, UTP20, SHQ1, and PIH1D2 between EGFR, NF1and PTEN mutant and wild-type groups, respectively. (D) Kaplan-Meier curves demonstrating the difference in overall survival of glioma patients between the IDH1, CIC and ATRX mutation and wild-type groups. (E) Differential expression of NOP10, UTP20, SHQ1, and PIH1D2 between IDH1, CIC and ATRX mutant and wild-type groups, respectively.*p < 0.05, **p < 0.01, ***p < 0.001, **** p < 0.0001.

Article Snippet: The membranes were blocked with 5% skimmed milk and then incubated overnight at 4 °C with primary antibodies: UTP20 (Proteintech, 18830-1-AP) and β-actin (Abmart, P30002 ).

Techniques: Mutagenesis, Quantitative Proteomics

Journal: Frontiers in Immunology

Article Title: Ribosome biogenesis-related gene signature predicts prognosis and immune landscape in glioma and identifies UTP20 as a therapeutic target

doi: 10.3389/fimmu.2025.1680667

Figure Lengend Snippet: Knockdown of UTP20 expression inhibited proliferation and invasion of glioma U251 and U87 cells in vitro . (A) UTP20 mRNA levels in U87 and U251 cells after knockdown. (B) Western Blot showing UTP20 protein levels in U87 and U251 cells after knockdown. (C, D) MTS assay for cell proliferation in U87 and U251 after UTP20 knockdown. (E) Colony formation assay showing the number of colonies in U87 and U251 after UTP20 knockdown. (F) Quantification of colonies formed in U87 and U251 cells after UTP20 knockdown. (G) Transwell invasion assay showing cell migration in U87 and U251 cells. (H) Quantification of cell migration in U87 and U251 cells. ***p < 0.001. One-way ANOVA with Tukey’s test for (A, F) , and (H) Two-way ANOVA with Tukey’s test for (C, D) .

Article Snippet: The membranes were blocked with 5% skimmed milk and then incubated overnight at 4 °C with primary antibodies: UTP20 (Proteintech, 18830-1-AP) and β-actin (Abmart, P30002 ).

Techniques: Knockdown, Expressing, In Vitro, Western Blot, MTS Assay, Colony Assay, Transwell Invasion Assay, Migration

Journal: Journal of Lipid Research

Article Title: Selective knockdown of ceramide synthases reveals complex interregulation of sphingolipid metabolism

doi: 10.1194/jlr.m009142

Figure Lengend Snippet: Fig. 2. CerS2 and CerS6 downregulation by targeted siRNA causes multiple changes in nontargeted CerS mRNA levels. A and B: MCF-7 cells were transfected with 5 nM siRNA targeted against CerS (black bars) or siControl (white bars) for 48 h. Cells were harvested, and RNA was extracted for q-PCR analysis of expression of CerS1-6. q-PCR data are normalized to -actin mRNA expres- sion, and data are means ± standard errors of the mean (SEM) for three independent experiments. A: Effects of siCerS2 on CerS1-6 expression. B: Effects of siCerS6 on CerS1-6 expression. C: Western blot analysis of CerS2, CerS6, and -actin protein expression fol- lowing transfection with siCerS1-6. CerS2 and CerS6 were detected using monoclonal antibodies specifi c for these proteins. -actin protein levels were used as a control for equal gel loading. *, P < 0.05; **, P < 0.01; ***, P < 0.01 versus siControl.

Article Snippet: Lysates were subjected to Western analysis using antibodies against CerS2 (mouse monoclonal, clone 1A6; Novus Biologicals, Littleton, CO) and CerS6 (mouse monoclonal, clone 5H7; Novus Biologicals).

Techniques: Transfection, Expressing, Western Blot, Bioprocessing, Control

Journal: Journal of Lipid Research

Article Title: Selective knockdown of ceramide synthases reveals complex interregulation of sphingolipid metabolism

doi: 10.1194/jlr.m009142

Figure Lengend Snippet: Fig. 4. CerS2 downregulation results in a shift of sphingolipid distribution to predominantly long- chain species, resulting in the accumulation of C16:0- SM and long-chain glycosphingolipids. The effects of siCerS2 (black bars) on Cer (A), dHCer (B), SM (C), HexCer (D), and LacCer (E) compared with siCon- trol (white bars) were determined as described in Fig. 4 . Sphingolipid levels are normalized to the amount of total lipid phosphate. Data are means ± SEM for three to fi ve independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.01 versus siControl.

Article Snippet: Lysates were subjected to Western analysis using antibodies against CerS2 (mouse monoclonal, clone 1A6; Novus Biologicals, Littleton, CO) and CerS6 (mouse monoclonal, clone 5H7; Novus Biologicals).

Techniques:

Journal: Journal of Lipid Research

Article Title: Selective knockdown of ceramide synthases reveals complex interregulation of sphingolipid metabolism

doi: 10.1194/jlr.m009142

Figure Lengend Snippet: Fig. 6. Knockdown of CerS2 or CerS6 increases total levels of a particular sphingolipid classes but does not signifi cantly elevate sphingoid bases. MCF-7 cells were transfected with siCerS1-6 or si- Control as described in Fig. 3, and total levels of different sphingo- lipid classes were determined by HPLC/MS. A: Total levels of dHCer, Cer, SM, HexCer, and LacCer were determined following CerS knockdown. B: dHSph and Sph levels were determined fol- lowing CerS knockdown. Sphingolipid levels are normalized to the amount of total lipid phosphate. Data are means ± SEM for three to fi ve independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.01 versus siControl.

Article Snippet: Lysates were subjected to Western analysis using antibodies against CerS2 (mouse monoclonal, clone 1A6; Novus Biologicals, Littleton, CO) and CerS6 (mouse monoclonal, clone 5H7; Novus Biologicals).

Techniques: Knockdown, Transfection, Control

Journal: Journal of Lipid Research

Article Title: Selective knockdown of ceramide synthases reveals complex interregulation of sphingolipid metabolism

doi: 10.1194/jlr.m009142

Figure Lengend Snippet: Fig. 7. Treatment of of siCerS2, siCerS5, and siCerS6 combined increases dHCer and HexCer levels and causes elevation of Sph and S1P. The effects of combined treatment of siCerS2 (10 nM), siCerS5 (20 nM), and siCerS6 (10 nM) (siCerS2/5/6) on CerS2, CerS5, and CerS6 expression compared to siControl (40 nM) were analyzed by real-time q-PCR (A). Data are means ± SEM for six in- dependent experiments. B: The effects of siCerS2/5/6 on total levels of dHCer, Cer, SM, HexCer, and LacCer were assessed by HPLC/MS. Data are means ± SEM for six independent experi- ments. C: Analysis of changes in individual HexCer species in re- sponse to siCerS2/5/6. Data are means ± SEM for six independent experiments. D: Changes in Sph and S1P content of cells treated with siCerS2/5/6 or siControl. Data are means ± SEM for six inde- pendent experiments. E: Effect of siCerS2/5/6 treatment on CHOP expression. Data are means ± SEM for fi ve independent ex- periments. *, P < 0.05; **, P < 0.01; ***, P < 0.01 versus siControl.

Article Snippet: Lysates were subjected to Western analysis using antibodies against CerS2 (mouse monoclonal, clone 1A6; Novus Biologicals, Littleton, CO) and CerS6 (mouse monoclonal, clone 5H7; Novus Biologicals).

Techniques: Expressing

Journal: Endocrinology

Article Title: The progesterone receptor in human term amniochorion and placenta is isoform C.

doi: 10.1210/en.2005-0510

Figure Lengend Snippet: FIG. 1. Identification of PR-positive cell types at the fetal-maternal interface. A, Low-power image of fetal membranes showing the immu- nohistochemical staining patterns obtained with antibodies that detect all isoforms of PR (clone 1A6; 1:50) and (C-20; 1:40), antibodies that detect only PR-B (San27, 1:150) and antibodies that detect only PR-A (clone 16; 1:200). An equivalent amount of mouse immunoglobulins (IgG) or antibody preadsorbed with immunizing peptide (BP), against which C-20 antibodies were generated, indicates specificity. Immunoreactivity is indicated with the black arrows in the amniotic (a), the star in the chorionic (c), and red arrows in the decidual (d) layers of the fetal membranes. B, The presence of cytoplasmic PR and an absence of PR-B and PR-A isoforms are demonstrated in term amnion epithelial cells (1, 4, 7, and 10,respectively)andchorioniccytotrophoblasts(2,5,8,and11,respectively).Bothcytoplasmicandstrongnuclearstainingwasobservedinthedecidua (3, 6, 9, and 12), indicating the presence of cytoplasmic and nuclear PR isoforms. C, High-power images of PR immunostaining with clone 1A6, indicating immunoreactivity in the cytoplasm of the amnion epithelial cell (1) and chorionic cytotrophoblast (2). Note the absence of staining in the blue nucleus of either cell type. D, A low-power image of PR immunostaining of the term placenta with clone 1A6 antibodies, indicating immuno- reactivity in the syncytiotrophoblast layer, but absent elsewhere. E, High-power images of PR immunostaining of term placenta, indicating the presence of cytoplasmic PR in the syncytiotrophoblast but not nuclear PR-B and PR-A isoforms (E; 1, 2, and 3); whereas basal plate decidual cells contained both cytoplasmic and nuclear PR isoforms (4, 5, and 6, arrowed). These data suggest the cytoplasmic PR staining in amnion epithelial cells, cytotrophoblasts, syncytiotrophoblasts, and decidual cells is not PR-B or PR-A but PR-S, PR-M, or PR-C. Data are representative of six independent samples. Images were obtained at magnification 100 (A), 1000 (B), 4000 (C), 200 (D), and 400 (E).

Article Snippet: Primary antibody, PR clones 1A6, San27, clone 16, or the polyclonal antibody C-20 (SC-539; Santa Cruz Biotechnology, Santa Cruz, CA) were applied at the indicated concentrations (Fig. 1) in 10% nonimmune rabbit serum or 10% swine serum overnight at 4 C. In some studies, C-20 antibodies were preincubated (3 h at room temperature) with a 7-fold excess of immunizing peptide before use.

Techniques: Staining, Generated, Immunostaining

Journal: Endocrinology

Article Title: The progesterone receptor in human term amniochorion and placenta is isoform C.

doi: 10.1210/en.2005-0510

Figure Lengend Snippet: FIG. 3. Confirmation that the PR isoform in human fetal membranes at term is primarily PR-C. A, Protein extracts from fetal membrane samples that had decidua attached (lane 1) and fetal membranes that had the decidua scraped away (lane 2) were compared with extracts from term amnion (lane 3), chorion (lane 4), and decidua (lane 5) that were obtained from crude tissue separation methods and term pla- centa (lane 6), myometrium (lane 7), and breast cancer (T47D cell) extracts (lane 8). The antibody clones used were 1A6 (upper series) that detects all PR isoforms (see lane 8) and C-20 (lower series) that detects additional isoforms (see lane 8). The data indicate the pres- ence of a major PR isoform of approximately 60 kDa in all the fetal membrane samples and that tissues contaminated with decidua were devoid of significant levels of the PR-B but contain small amounts of PR-A isoforms that are easily detected in myometrium and T47D cell controls. Placenta and term decidua also indicate the presence of PR-C as the major PR isoform, although other PR isoforms were observed. The 38-kDa PR-M isoform was observed only in the tissues contaminated with deciduas and T47D extracts with these antibodies. B, Confirmation that the antibodies detect the 60-kDa PR-C isoform was obtained by immunoblotting an extract obtained from human choriocarcinoma (BeWo) cells transiently transfected with a human PR-C and probed with C-20 antibodies () or C-20 antibodies pread- sorbed with immunizing peptide (). C, Further confirmation of the nature of the main PR isoform in the amnion was obtained by probing immunoblot extracts of T47D (control) and term amnion (Am) with the 1A6 antibody clone preabsorbed with BeWo cell extracts (no trans- fection) or BeWo extracts transiently transfected with human PR-C (hPRc) or PR-A (hPRa) expression plasmids. These data indicate that only hPRc significantly inhibited the immunoreactivity of the ap- proximately 60-kDa band, suggesting that this protein is the PR-C isoform.

Article Snippet: Primary antibody, PR clones 1A6, San27, clone 16, or the polyclonal antibody C-20 (SC-539; Santa Cruz Biotechnology, Santa Cruz, CA) were applied at the indicated concentrations (Fig. 1) in 10% nonimmune rabbit serum or 10% swine serum overnight at 4 C. In some studies, C-20 antibodies were preincubated (3 h at room temperature) with a 7-fold excess of immunizing peptide before use.

Techniques: Membrane, Clone Assay, Western Blot, Transfection, Control, Expressing

Journal: PLoS ONE

Article Title: UGT1A6 Polymorphisms Modulated Lung Cancer Risk in a Chinese Population

doi: 10.1371/journal.pone.0042873

Figure Lengend Snippet: UGT1A6*1 and UGT1A6 105TT constructs were stably transfected into HEK293 cells. ( A ) Cells were harvested upon treatment with ActD at different time point up to 24 hours. The data plotted are time course changes in the remaining amount of UGT1A6 mRNA after ActD treatment. There was significantly higher mRNA level in UGT1A6 105TT than UGT1A6*1 transfected cells at 4 hours (p = 0.039) and 8 hours (p = 0.004) after treatment with ActD. ( B ) Western blot analysis. Cell lysate used was from 5×10 5 cells at the indicated times (0, 8, 24 and 48 hours) after treatment with ActD. There was a down-regulation in protein expression in UGT1A6*1 as compared to UGT1A6 variant at 48 hours after treatment with ActD. UGT1A6 activity was assessed by evaluating the production of serotonin glucuronide using lysate from variant UGT1A6 (VT) and UGT1A6*1 (WT) at 0 hour ( C ) and 48 hours ( D ) after ActD treatment, with substrate concentrations varied from 0.5 to 30 mM serotonin. Activities are expressed as reaction velocity (nanomoles of serotonin glucuronide formed per minute per milligram of protein).

Article Snippet: After blocking, the membrane was probed using a rabbit anti-human UGT1A6 primary antibody diluted 1∶1000 (WB-UGT1A6; BD Gentest, Woburn, MA) and a goat anti-rabbit horseradish peroxidase-conjugated secondary antibody (1∶10,000 diluted).

Techniques: Construct, Stable Transfection, Transfection, Western Blot, Expressing, Variant Assay, Activity Assay

Journal: PLoS ONE

Article Title: UGT1A6 Polymorphisms Modulated Lung Cancer Risk in a Chinese Population

doi: 10.1371/journal.pone.0042873

Figure Lengend Snippet: Genotype and allele frequencies of UGT1A6 SNPs in both first and second cohorts.

Article Snippet: After blocking, the membrane was probed using a rabbit anti-human UGT1A6 primary antibody diluted 1∶1000 (WB-UGT1A6; BD Gentest, Woburn, MA) and a goat anti-rabbit horseradish peroxidase-conjugated secondary antibody (1∶10,000 diluted).

Techniques: